Who
Thomas Zindrick
President and CEO
Company insider
Files Form 4 as: President and CEO, Genelux.
In numbers
- Trades disclosed
- 34
- Buys
- 1
- Sells
- 9
- Bought
- $0
- Sold
- $565K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 27 Feb 2023
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $92K34,463 at $2.67 | filing |
| 31 Aug 2026filed 2 Sep 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $92K34,463 at $2.67 | filing |
| 4 Aug 2026filed 4 Aug 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $8,9053,023 at $2.95 | filing |
| 4 Aug 2026filed 4 Aug 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $8,9183,023 at $2.95 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —730,601 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —730,601 at $0.00 | filing |
| 11 May 2026filed 12 May 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $8,2262,798 at $2.94 | filing |
| 11 May 2026filed 12 May 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $8,2262,798 at $2.94 | filing |
| 24 Mar 2026filed 26 Mar 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $8,6683,582 at $2.42 | filing |
| 24 Mar 2026filed 26 Mar 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $8,6683,582 at $2.42 | filing |
| 17 Nov 2025filed 11 Dec 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $24K4,509 at $5.37 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code D | —925,000 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —925,000 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code D | —157,372 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —157,372 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,568 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,568 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code D | —250,000 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 | filing |
| 27 Aug 2025filed 29 Aug 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —478,800 at $0.00 | filing |
News
Genelux (NASDAQ:GNLX) Upgraded at Wall Street ZenGNLX · dailypolitical.com · 23 Oct 2026Head-To-Head Analysis: Foghorn Therapeutics (NASDAQ:FHTX) vs. Genelux (NASDAQ:GNLX)GNLX · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Thomas Zindrick; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.